JPRN-jRCT2031220316招募中3 期
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluatethe Efficacy and Safety of AVT06 Compared with EU-Eylea in Subjects with Neovascular (wet)Age-related Macular Degeneration (ALVOEYE)
Koelbl Stephanie0 个研究点目标入组 62 人开始时间: 2022年9月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subject must be >= 50 years of age, at the time of signing the informed consent.
- •- Subjects must be diagnosed with neovascular (wet) AMD in the study eye.
- •- Subjects must have active, treatment naive, subfoveal CNV lesions secondary to neovascular (wet) AMD.
- •- Willingness and ability to undertake all scheduled visits and assessments.
排除标准
- •- Any prior systemic treatment with anti-VEGF therapy
- •- Any condition that, in the Investigator's opinion, can interfere with full participation in the study, including administration of the study treatment and attending required visits; can pose a significant risk to the participant, or interfere with interpretation of study data
- •- Prior treatment with any investigational drugs within 30 days or 5 half-lives (whichever is longer) of the previous investigational treatment before initiation of the study treatment or concomitant enrollment in any other clinical study involving an investigational study treatment
- •- Subjects not suitable for participation, whatever the reason, as judged by the Investigator, including medical or psychiatric conditions, or participants potentially at risk of noncompliance to study procedures.
研究者
相似试验
进行中（未招募）
1 期
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)eovascular (wet) Age-related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-003651-42-LVAlvotech Swiss AG690
招募中
1 期
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)eovascular (wet) Age-related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-003651-42-BGAlvotech Swiss AG690
招募中
1 期
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)eovascular (wet) Age-related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-003651-42-LTAlvotech Swiss AG690
进行中（未招募）
1 期
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)eovascular (wet) Age-related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-003651-42-SKAlvotech Swiss AG690
招募中
1 期
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)eovascular (wet) Age-related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-003651-42-CZAlvotech Swiss AG690